For instance, BMAL1 knockdown enhances glycolysis in primary colon cancer cells but reduces it in metastatic cancer cell lines from mesenteric lymph nodes, whereas CAFs derived from CRC patients paradoxically demonstrate suppressed glycolytic activity [105]. This evidence concerns the gene BMAL1 and colorectal carcinoma.